Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens

John Craddock, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Adoptive T-cell therapy is an attractive option for targeting tumors associated with Epstein-Barr virus. In immunogenic Type III latency tumors such as post transplant lymphoproliferative disease, EBV-specific CTL have been used successfully as prophylaxis and treatment. In Type II latency malignancies such as Hodgkin's disease and nasopharyngeal cancer, a more restricted array of EBV antigens are encoded and the clinical response rates after infusion of EBV-specific CTLs have been lower. Current strategies to increase response rates include targeting CTL to subdominant EBV antigens and genetically modifying CTL to increase their potency.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalUpdate on Cancer Therapeutics
Issue number1
StatePublished - Mar 2008


  • Adoptive immunotherapy
  • EBV
  • EBV specific CTLs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens'. Together they form a unique fingerprint.

Cite this